iiinova — where your digital self keeps evolving

🚨 New speakers added to the Ecraid Foundation Science Meeting 2027 programme! Join the infectious diseases community in Verona to exchange knowledge, build collaborations and shape future research. 🔎More information about the event: www.ecraid.eu/news/join-3r... #InfectiousDiseases #AMR

110

Ecraid @ecraid.bsky.social · 30/09/2026

From prevention to ICU care, ID research requires connected expertise. Through studies such as POS-VAP, REMAP-CAP and research programmes like NOFLU and STRIDE-CAP, Ecraid brings together experts, sites & partners across Europe to generate evidence that improves patient care: eu1.hubs.ly/H0y9_k_0

011

Ecraid @ecraid.bsky.social · 29/09/2026

A respiratory virus was detected in roughly two out of three patients, incl. #humanrhinovirus, #influenza A/B and seasonal #coronaviruses. Read about the findings on ecraid.eu/news/ecraid-... @christophercbutler.bsky.social @ema.europa.eu @ecdc.europa.eu @lenniederde.bsky.social @vcstx.bsky.social

000

Ecraid @ecraid.bsky.social · 29/09/2026

At the recent #ESCV2026, Katherine Loens from the Laboratory of Medical Microbiology at @uantwerpen.be presented her team's findings from the #ECRAIDPrime study on the Etiology of Respiratory Infections in Non-hospitalised Patients. @horizoneu.bsky.social @ec.europa.eu @euinemergencies.ec.europa.eu

210

Ecraid @ecraid.bsky.social · 25/09/2026

Pharma Holdings CEO Chris Lütken shares how the EU-funded ECRAID-Prime trial's adaptive design and #primarycare research setting, and access to Ecraid's network, made the #researchcollaboration an excellent fit for evaluating its intranasal #antiviral compound LTX-109: ecraid.eu/news/intervi...

ecraid.eu

Interview with Christian Lütken on his partnership with Ecraid | Ecraid

100

Ecraid @ecraid.bsky.social · 24/09/2026

🏠 Decentralised trials was a key theme discussed at the #ICTMC2026 last week. Emma Harper and Nicky Maeder from @oxprimarycare.bsky.social presented the #ECRAIDPrime poster to share learnings from the EU-funded #adaptiveplatformtrial in #primarycare.

100

Ecraid @ecraid.bsky.social · 22/09/2026

🔎Expert spotlight: Jake Dunning. Discover why collaborative hospital #research networks are key to advancing #respiratory innovation and how Ecraid supports high-quality evidence generation and efficient studies. 👉🏾Meet one of the experts behind the impact: eu1.hubs.ly/H0ytDlL0 #PartnerForImpact

100

Ecraid @ecraid.bsky.social · 21/09/2026

📩 Did you read our September newsletter? 🚀 Discover the latest from across the Ecraid ecosystem, including WHO Industry Dialogue support, expert insights, upcoming events, educational opportunities & registration for the Ecraid Foundation Science Meeting 2027. 👉🏾Subscribe: mailchi.mp/ecraid/newsl...

100

Ecraid @ecraid.bsky.social · 20/09/2026

🔎 Expert Spotlight: Alike van der Velden. Most ARIs are managed in primary care, where treatment decisions are made under diagnostic uncertainty. Through ECRAID-Prime, POS-ARI-PC and a warm-base network, Ecraid generates evidence to improve care and tackle #AMR. 👉🏾 eu1.hubs.ly/H0y1n1l0

100

Ecraid @ecraid.bsky.social · 18/09/2026

🚀At #GAMRIC2026 in Lisbon (22-24 Sept)? Let’s connect! At Ecraid, impact is powered by people. Our experts are not only contributors to individual studies, they are the foundation of a uniquely connected European research ecosystem. 👉🏽Connect with our experts at GAMRIC: www.ecraid.eu/get-in-touch

100

Ecraid @ecraid.bsky.social · 16/09/2026

We’re also pleased to continue our collaboration with the STRIDE-CAP Full Study, evaluating the real-world effectiveness of the adult-specific #pneumococcal conjugate vaccine V116. Thank you to the MSD team for the great collaboration! We look forward to what’s ahead. #ResearchCollaboration #AMR

000

Ecraid @ecraid.bsky.social · 16/09/2026

🎉 We’re pleased to celebrate the successful completion of enrolment in our #PNEUMOstudy with MSD: 9008 patients consented across 54 sites in 6 European countries, with 8850 evaluable participants. 📊 Recruitment has concluded, but scientific dissemination and knowledge sharing continue! #Pneumonia

100

Ecraid @ecraid.bsky.social · 14/09/2026

On #WorldSepsisDay, we’re reminded that sepsis is not caused by bacteria alone. At the Lund Conference on Sepsis, Ecraid CEO @lenniederde.bsky.social shared insights on #adaptivetrialdesigns, which can help researchers evaluate treatments more efficiently and respond to emerging evidence.

210

Reposted by Ecraid

ESCMID @escmid.bsky.social · 06/09/2026

⏳ Registration deadline extended! ow.ly/PatN50ZGyz7 Build practical clinical research skills at this onsite course, covering study design, bias reduction, scientific writing and the latest in clinical trial methodology. Registration closes on Tues, 15 September!

023

Ecraid @ecraid.bsky.social · 11/09/2026

Why Expertise Networks Matter in Respiratory Diseases Acute respiratory infections drive healthcare visits & antibiotic use, yet diagnosis remains uncertain, contributing to #AMR. Ecraid connects respiratory experts across Europe - Want to advance respiratory research? Connect: eu1.hubs.ly/H0y9_k_0

210

Ecraid @ecraid.bsky.social · 10/09/2026

Impactful ID & AMR research starts with connection. Ecraid unites Europe's ID expertise & clinical research networks: 🌍 40+ countries 🏥 1,200+ hospital sites 🩺 250+ primary care sites One point of access for coordinated, high-quality research. 👉🏾 Speak to our experts: eu1.hubs.ly/H0y9_k_0

000

Ecraid @ecraid.bsky.social · 09/09/2026

🗞️ Get the latest updates on Europe's academic infectious disease network in our September 2026 newsletter: www.linkedin.com/feed/update/...

linkedin.com

Advancing Priority Antibiotics Development | Ecraid

🗞️ Get the latest updates on Europe's academic infectious disease network in our September 2026 newsletter.

100

Ecraid @ecraid.bsky.social · 07/09/2026

📅 10 Sept | 11:00-12:00 CET #AMR innovators: looking to turn European funding opportunities into clinical impact? Join the BEAM Alliance webinar, presented by Ecraid, for practical insights on Horizon Europe 2027, partnerships & development strategies. 👉🏽 Register: us06web.zoom.us/meeting/regi...

000

Ecraid @ecraid.bsky.social · 04/09/2026

On 31 Aug, the @who.int convened 153 participants from industry, academia & regulatory bodies to discuss the challenges of #antibioticdevelopment and solutions. Ecraid was contribute to the dialogue, and will help develop analyses to support future WHO guidance on #evidencegeneration.

100

Ecraid @ecraid.bsky.social · 03/09/2026

📢 Registration is now open for the Ecraid Foundation Science Meeting 2027, taking place in Verona, Italy, on 2-3 February. Join leading experts in infectious diseases and AMR research for two days of science, collaboration, and networking. 🔗 Register now: www.eventbrite.nl/e/ecraid-fou...

111

Ecraid @ecraid.bsky.social · 01/09/2026

We're pleased to partner with BEAM Alliance for the webinar Advancing AMR Innovation through European Funding, Partnerships and Clinical Research. 👉🏽 Explore how collaboration can help innovators navigate EU funding opportunities & accelerate AMR innovation. 🔗 Register here: lnkd.in/eiTfquGC

000

Ecraid @ecraid.bsky.social · 31/08/2026

Heading to #ERSCongress 2026 in Barcelona (5-9 September)? Let's connect. 🤝🏽 Meet our team and discover how studies such as POS-VAP, PNEUMO, STRIDE-CAP, and POS-ARI-ER are advancing respiratory research. We'll also be featuring experts from across the Ecraid network throughout the month. Stay tuned!

100

Ecraid @ecraid.bsky.social · 27/08/2026

𝐇𝐨𝐰 𝐜𝐚𝐧 𝐞𝐯𝐢𝐝𝐞𝐧𝐜𝐞 𝐠𝐞𝐧𝐞𝐫𝐚𝐭𝐢𝐨𝐧 𝐟𝐨𝐫 𝐩𝐫𝐢𝐨𝐫𝐢𝐭𝐲 𝐚𝐧𝐭𝐢𝐛𝐢𝐨𝐭𝐢𝐜𝐬 𝐛𝐞𝐭𝐭𝐞𝐫 𝐬𝐮𝐩𝐩𝐨𝐫𝐭 𝐛𝐨𝐭𝐡 𝐫𝐞𝐠𝐮𝐥𝐚𝐭𝐨𝐫𝐲 𝐚𝐩𝐩𝐫𝐨𝐯𝐚𝐥 𝐚𝐧𝐝 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐮𝐬𝐞? 🌍 Join the WHO Industry Dialogue with priority antibacterial agent developers to explore the realities of global #antibioticdevelopment and where future WHO guidance could add value.

123

Ecraid @ecraid.bsky.social · 25/08/2026

Training the next generation of #ID & #AMR researchers means more than sharing knowledge. It means creating connections. The Ecraid x ESCMID Postgraduate Course links participants to experts, peers, and research networks, turning education into future collaboration. Join us in Verona: bit.ly/48jUgdg

100

Ecraid @ecraid.bsky.social · 21/08/2026

How can education strengthen Europe's response to #ID and #AMR? Dr. Despoina Koulenti highlights the power of collaboration, mentorship, and professional networks in our latest Expert Spotlight. 👉🏽Read more and discover our educational opportunities: bit.ly/Education_De... #KnowledgeSharing

000

Ecraid @ecraid.bsky.social · 20/08/2026

🤧 As the project reaches its goals, maintaining and building on this platform will be essential to keeping Europe ready to respond to the next #infectiousdisease threat. Read about the trial ecraid.eu/ecraid-prime...

100

Ecraid @ecraid.bsky.social · 20/08/2026

#ECRAIDPrime is the only operationally ready #adaptiveplatformtrial of its kind, designed to learn, adapt and evaluate new treatments in general practice and community settings across Europe – and ready to respond rapidly and generate evidence when needed.

100

Ecraid @ecraid.bsky.social · 04/08/2026

Read Ecraid’s July news already? 📩 Discover the latest research, the SNAP trial results, new publications, expert interviews, our 2025 Annual Report, and upcoming events. 👉🏼 Subscribe to our monthly newsletter: mailchi.mp/ecraid/newsl... #InfectiousDiseases #ClinicalResearch #PandemicPreparedness

001

Ecraid @ecraid.bsky.social · 20/07/2026

Henri van Werkhoven explains that training researchers is not just about teaching methods - it is about helping them directly improve the quality and impact of their own research. Meet the expert: ecraid.eu/news/advanci...

010

Ecraid @ecraid.bsky.social · 16/07/2026

The Ecraid 2025 Annual Report reflects on a year of important milestones, with highlights from our research and education activities. A balanced reflection, celebrating our achievements while sharing what we learned from the challenges we faced. Discover it here: drive.proton.me/u/0/3r3ZZUJd...

000

Ecraid @ecraid.bsky.social · 07/07/2026

#Education is an essential tool for advancing clinical research in ID and AMR. At Ecraid, learning is embedded in a European network, connecting education with research & collaboration. 👉🏽Discover the Ecraid x ESCMID Postgraduate Course in Verona and meet our experts: bit.ly/48jUgdg

011

Ecraid @ecraid.bsky.social · 02/07/2026

Pandemic preparedness begins before a crisis arises. Yazdan Yazdanpanah explains why “ever-warm” research & clinical networks are essential for responding to emerging threats. 🦠 Strong partnerships & ongoing collaboration are helping build a more resilient future. 👉🏽Read how: bit.ly/Expert_Yazdan

000

Ecraid @ecraid.bsky.social · 30/06/2026

Behind every trial result: dedication, commitment & collaboration. The SNAP Trial unites 150+ hospitals in 14+ countries to tackle one of the most serious bloodstream infections. Its impact comes from experts & partnerships driving coordinated, high-impact research for patient care: bit.ly/SNAPTrial

010

Ecraid @ecraid.bsky.social · 29/06/2026

📩 Our latest newsletter is out! Discover: Verona methodology course, ECRAID‑Prime milestone, pandemic preparedness across Europe & contribution to the WHO NAVIS protocol for Hantavirus, STRIDE‑CAP vaccine study, and Ecraid's 2027 Science Meeting. 👉🏽Stay informed—subscribe now: bit.ly/news-june-26

010

Ecraid @ecraid.bsky.social · 25/06/2026

💡 New publication - scientific correspondence in BMC Critical Care on #VAP epidemiology! The complete scientific dialogue - including the original manuscript, peer commentary, and authors' response - is available here 🔗 bit.ly/4w2xkZA #ClinicalEpidemiology #InfectiousDiseases #VAP #STATNet

000

Ecraid @ecraid.bsky.social · 22/06/2026

Save the Date: Ecraid Foundation Science Meeting 2027, Verona (2–3 Feb). Join Europe’s infectious diseases & AMR community. Partners from academia, healthcare, industry, and public health will share insights, collaborate, and shape future research. Details to follow. For info: events@ecraid.eu

111